Table 3. Phase II/III trials with EML4-ALK and proteasome inhibition.
| TREATMENT | REFERENCE/ STUDY PHASE | PATIENTS | RESPONSES | SURVIVAL |
| CRIZOTINIB | ||||
| Crizotinib | Kwak E. 2010 | 82 patients | 57% ORR 33% SD |
Median PFS at six months 72% |
| BORTEZOMIB | ||||
| Bortezomib | Southwest Oncology Group 0327 Phase II | 56 (previously treated) | 91% DP | Median PFS 1 month Median OS 3 months |
| Bortezomib +/-Docetaxel | Fanucchi MP 2006 Phase II | 155 (previously treated) | ORR 8 vs 9% | OS 7.8 versus 7.4 months Time to disease progression 1.5 vs 4 months |
| Bortezomib + Gembitabine/Carboplatin | Davies AV 2009 Phase II (S0339) | 114 naïve advanced NSCLC patients | ORR 23% DCR 68% |
Median OS 11 months 1-year and 2-year survival rates 47% and 19% Median PFS 5 months |
| Bortezomib + Erlotinib vs Erlotinib | Lynch TJ 2009 Phase II | 50 relapsed or refractory stage IIIb/IV NSCLC | ORR 16% vs 9%Response rate with EGRF mutation 50 vs 9% | Median PFS 2.7 months Median OS 7.3 Combination: Median PFS 1.3 months Median OS 8.5 months |
EGFR: epidermal growth-factor receptor; ORR: overall response rate; SD: stable disease; PR: partial response; PFS: progression-free survival; OS: overall survival; DP: disease progression